Skip to main content

Month: April 2021

Orchard Therapeutics Announces Multiple Presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy

Seven abstracts accepted show the potential of HSC gene therapy to transform the treatment of multiple severe rare disorders First peer-reviewed presentation from company’s work in transduction enhancers showcases promise to improve manufacturing efficiency of lentiviral-based gene therapy BOSTON and LONDON, April 28, 2021 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the acceptance of seven abstracts at the 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place virtually from May 11-14. Accepted abstracts include clinical data from several of its hematopoietic stem cell (HSC) gene therapy programs, including: OTL-203, being investigated for the treatment of mucopolysaccharidosis type I (MPS-I), and OTL-101, being investigated for the...

Continue reading

Trillium Therapeutics Announces Dosing of First Patient in Phase 1b Study of TTI-622 in Combination With Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) — Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first multiple myeloma patient with TTI-622 (SIRPα-IgG4 Fc), an investigational checkpoint inhibitor of the innate immune system, in combination with the proteasome inhibitor carfilzomib and dexamethasone. TTI-622 is a fusion protein that is designed to block the inhibitory activity of CD47, a molecule that is overexpressed by a wide variety of tumors. CD47 binds to SIRPα on macrophages and delivers a “don’t eat me” signal that inhibits the ability of macrophages to engulf and destroy cancer cells. Preclinical studies have shown that TTI-622 exhibits anti-myeloma activity as a monotherapy that...

Continue reading

Hiab to supply UK’s Marshall with 108 new HIAB loader cranes

HIAB XS 099 HiProHIAB XS 099 HiProHIAB XS 099 HiPro on roadHIAB XS 099 HiPro on roadHIAB XS 099 HiPro operatorHIAB XS 099 HiPro operator HIAB XS 099 HiProCARGOTEC CORPORATION, PRESS RELEASE APRIL 28 2021 AT 1:45 PM EEST Hiab, part of Cargotec, will supply the leading UK hard landscaping manufacturer Marshalls with 108 new HIAB loader cranes equipped with the connected service HiConnect™ and ProCare™ Total Repair and Maintenance contracts for eight years. The order value of EUR 4.9 million were ordered and booked in Cargotec’s quarter 1 order intake of 2021. Marshalls is a complete external landscaping products business – from planning to engineering, to guidance and delivery. From the highlands of Scotland to England’s southern tip, they offer a three-day delivery promise,...

Continue reading

Steve Madden Announces First Quarter 2021 Results

LONG ISLAND CITY, N.Y., April 28, 2021 (GLOBE NEWSWIRE) — Steven Madden, Ltd. (Nasdaq: SHOO), a leading designer and marketer of fashion-forward footwear, accessories and apparel for women, men and children, today announced financial results for the first quarter ended March 31, 2021. Amounts referred to as “Adjusted” exclude the items that are described under the heading “Non-GAAP Adjustments.” First Quarter 2021 ReviewRevenue increased 0.5% to $361.0 million compared to $359.2 million in the same period of 2020. Gross margin increased 130 basis points to 38.5% compared to 37.2% in the same period of 2020. Operating expenses as a percentage of revenue were 30.6% compared to 33.8% in the same period of 2020. Adjusted operating expenses as a percentage of revenue were 28.7% compared to 33.2% in the same period of 2020. Income...

Continue reading

Wabash National Corporation Announces First Quarter 2021 Results

Revenue of $392.0 million, which is within prior guidance range Operating income of $11.2 million and operating margin of 2.9% both show sequential improvement Net Income of $3.2 million or earnings per share of $0.06 Backlog of $1.5 billion up 57% YoY; outperforms normal sequential seasonality 2021 EPS outlook maintained at $0.75 per diluted share; range of $0.70 to $0.80LAFAYETTE, Ind., April 28, 2021 (GLOBE NEWSWIRE) — Wabash National Corporation (NYSE: WNC), the innovation leader of engineered solutions for the transportation, logistics and distribution industries, today reported results for the quarter ended March 31, 2021. Net sales for the first quarter 2021 of $392.0 million increased 1.3% versus the prior year quarter as the Company continued to scale its ability to serve strong customer demand. Consolidated gross profit...

Continue reading

Offer for Subscription Extension

Downing ONE VCT plc 28 April 2021LEI: 213800R88MRC4Y3OIW86  Offer for Subscription Extension The Board of Downing ONE VCT plc is pleased to announce an extension of the Offer for Subscription that launched on 11 September 2020. The Offer had previously been scheduled to close on 30 April 2021 but has now been extended to 3 p.m. on 31 August 2021 (unless previously fully subscribed).

Continue reading

DeepVerge enters into Memorandum of Understanding (“MoU”) for a Joint Venture with China Resources Environmental Protection Development Limited

China Resources will own 51% and DeepVerge will own 49% of the share capital MoU covers the manufacture, assembly and sale of environmental monitoring equipment DeepVerge PLC (“DeepVerge” or “the Company”) YORK, United Kingdom, April 28, 2021 (GLOBE NEWSWIRE) — DeepVerge (LSE:DVRG.L), the environmental and life science AI company, announces that it has signed a non-binding Memorandum of Understanding (“MoU”) with China Resources Environmental Protection Development Limited (“China Resources”), a wholly-owned subsidiary of China Resources Group, to enter into a Joint Venture (“JV”) for the manufacture, assembly and sale of environmental monitoring equipment, with a view to future development of smart environmental platforms, equipment/devices and network management software...

Continue reading

Nokia ranked as number one in 5G patents

Press Release Nokia ranked as number one in 5G patentsIndependent study by PA Consulting confirms Nokia’s leadership in 5G Standard Essential Patents The finding is the latest to rank Nokia number one for patents declared as essential for cellular standards, including 5G28 April 2021 Espoo, Finland – Nokia today announced that it has been ranked as number one in 5G patents in an independent study. The strength of Nokia’s industry leading 5G patent portfolio has once again been confirmed by an independent third party. In its study on Standard Essential Patents (published April 2021), independent analyst firm PA Consulting concluded that Nokia is number one for ownership of granted patents that the researchers found essential to 5G standards. This is the second time Nokia’s leadership in 5G Standard Essential Patents has been confirmed...

Continue reading

Sprott Asset Management Enters Into Agreement With Uranium Participation Corporation to Form the Sprott Physical Uranium Trust

TORONTO, April 28, 2021 (GLOBE NEWSWIRE) — Sprott Inc. (“Sprott”) (NYSE/TSX: SII) announced today that Sprott Asset Management LP (“Sprott Asset Management”), a wholly-owned subsidiary of Sprott has entered into a definitive agreement with Uranium Participation Corporation (“UPC”) (TSX: U) pursuant to which UPC shareholders will become unitholders of the Sprott Physical Uranium Trust (the “Trust”), a newly-formed entity managed by Sprott Asset Management. UPC is the world’s largest publicly traded investment vehicle providing investors an opportunity to gain exposure to the price of uranium, outside of a traditional mining company, through holdings of physical uranium in the form of uranium oxide in concentrates (“U3O8“) and uranium hexafluoride (“UF6“). At the end of March 2021, UPC reported holding 16,269,658...

Continue reading

Immunology Market Size 2021 | To Reach USD 143,833.2 Million with 8.1% CAGR by 2026

Top Players Covered in the Immunology Market Research Report Are AbbVie Inc., Janssen Global Services, LLC (Johnson & Johnson), F. Hoffmann-La Roche Ltd, Amgen Inc., Pfizer Inc, Novartis, Astellas, Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., UCB SA, ALLERGAN. and other key market players. Pune, India, April 28, 2021 (GLOBE NEWSWIRE) — The Global Immunology Market is likely to expand in the coming years driven by the high prevalence of immunological disorders, resulting from environmental factors. According to a report published by Fortune Business Insights, titled “Immunology Industry: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 77,365.4 Mn in 2018. Fortune Business Insights has predicted that the market will reach US$ 143,833.2 Mn by 2026 and will exhibit a CAGR...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.